Abstract | BACKGROUND: METHODS: From 1981 to 1994, 33 operable patients with locally advanced oral cavity cancer received cisplatin-based chemotherapy before surgery. Postoperative radiotherapy was performed in high-risk patients. RESULTS: The overall clinical and pathologic complete response rates to neoadjuvant chemotherapy were 48% and 30%, respectively. At a median follow-up of 7.0 years (range, 0.3-15.3+ years), the 5-year and 10-year overall survival rates were 54.5% and 39.5%, and the disease-specific median survival was 6.6 years for all patients (8.3 and 2.3 years for stages III and IV, respectively). The univariate analysis showed a positive relationship between survival and male sex (p = .05), pathologic (p = .02), and clinical (p = .03) complete response. The Cox proportional hazard regression model confirmed the independent prognostic value of the clinical response with a 4.67 (95% CI, 1.70-12.86) hazard ratio. A second primary tumor occurred in six patients (18%), with a median of occurrence of 9 years (range, 7-11 years). CONCLUSIONS: This study confirms the prolonged survival expectancy largely exceeding 5 years for selected patients with stage IV and for most with stage III locally advanced oral cavity cancer achieving a clinical and/or pathologic complete response to chemotherapy.
|
Authors | Enzo Maria Ruggeri, Paolo Carlini, Camillo Francesco Pollera, Salvatore De Marco, Paolo Ruscito, Paola Pinnarò, Mario Nardi, Diana Giannarelli, Francesco Cognetti |
Journal | Head & neck
(Head Neck)
Vol. 27
Issue 6
Pg. 452-8
(Jun 2005)
ISSN: 1043-3074 [Print] United States |
PMID | 15880411
(Publication Type: Journal Article)
|
Copyright | (c) 2005 Wiley Periodicals, Inc. |
Chemical References |
- Bleomycin
- Vincristine
- Vinblastine
- Doxorubicin
- Cisplatin
- Fluorouracil
- Methotrexate
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Bleomycin
(therapeutic use)
- Carcinoma, Squamous Cell
(drug therapy, pathology, surgery)
- Cisplatin
(therapeutic use)
- Doxorubicin
(therapeutic use)
- Female
- Fluorouracil
(therapeutic use)
- Humans
- Male
- Methotrexate
(therapeutic use)
- Middle Aged
- Mouth Neoplasms
(drug therapy, pathology, surgery)
- Neoadjuvant Therapy
- Neoplasm Staging
- Sex Factors
- Survival Analysis
- Time Factors
- Vinblastine
(therapeutic use)
- Vincristine
(therapeutic use)
|